Foundation Medicine, Inc.
NEWS
For its 2019 list of the top 50 most innovative companies, Fast Company selected 10 from the biotech industry that are having a significant impact on the treatment of patients. The first five are highlighted.
On August 29, Chicago-based Tempus, which focuses on data analytics for molecular and clinical data, announced it had raised $110 million in Series E financing. This brought total money raised so far to $320 million. This also gave the company a valuation of $2 billion.
Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of Spanish media group Intereconomia.
Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.
Three years after acquiring a majority stake Foundation Medicine, Pharma giant Roche has agreed to buy up all outstanding shares for about $2.4 billion and bring the company’s sequencing diagnostics platform under the Roche umbrella.
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
A look at the latest batch of FDA approvals this year.
Boston Business Journal pulled together a list of the 25 biggest gainers in the state for 2017, and five of them are biopharma companies.
JOBS
IN THE PRESS